What Are Inhibrx Biosciences Inc.'s Key Financial Figures?
| Fiscal year | FY2025 ended December 31, 2025 | FY2024 ended December 31, 2024 | FY2023 ended December 31, 2023 |
|---|---|---|---|
| Revenue | $1 million | $200,000 | $2 million |
| Operating income | -$135 million | -$331 million | -$219 million |
| Operating margin | -10386.5% | -165724.0% | -12178.9% |
| Net income | -$140 million | $1.7 billion | -$241 million |
| Net margin | -10773.5% | 843786.0% | -13408.9% |
| Operating cash flow | -$130 million | -$194 million | -$193 million |
| Capital expenditures | $31,000 | $3 million | $5 million |
| Free cash flow | -$130 million | -$197 million | -$198 million |
Operating margin widened by 155337.5 percentage points between fiscal 2024 and 2025, which separates pricing and cost discipline from revenue growth alone. Free cash flow (operating cash flow minus capital expenditures) was -$130 million against net income of -$140 million; cash generation covered reported earnings.
What Does Inhibrx Biosciences Inc.'s Balance Sheet Show?
| Cash and cash equivalents | $124 million |
|---|---|
| Long-term debt | $101 million |
| Total assets | $146 million |
| Total liabilities | $138 million |
| Shareholders' equity | $8 million |
| Current ratio | 3.9x |
Balance sheet values are as of the end of fiscal 2025. Income statement figures describe a whole year; balance sheet figures describe a single day, so the two answer different questions.
Where These Numbers Come From
Every figure on this page is a value Inhibrx Biosciences Inc. reported in its own SEC filings, read from the SEC's XBRL data (accession 0002007919-26-000006 for fiscal year 2025). Ratios are computed from those reported values. Figures were retrieved on October 7, 2026; a later amendment or a new annual report can change them, and the filing itself always takes precedence over this summary.
Each fiscal year is labeled by the calendar year in which it ended, so a company that names the same period differently in its own filings (many retailers whose year ends in January) may use another label. A year is left out of the table when the SEC data set holds no value for it. A figure shown as "Not reported" means the company did not file a value under the standard tag Swoopr reads, not that the amount was zero. This page is educational and describes reported history only; it is not a forecast or a recommendation.
Frequently Asked Questions
What was Inhibrx Biosciences Inc.'s revenue in fiscal 2025?
Inhibrx Biosciences Inc. reported revenue of $1 million for the fiscal year ended December 31, 2025, according to its SEC filings.
What is Inhibrx Biosciences Inc.'s operating margin?
Inhibrx Biosciences Inc.'s operating margin was -10386.5% in fiscal 2025: operating income of -$135 million on revenue of $1 million.
How much free cash flow did Inhibrx Biosciences Inc. generate?
Operating cash flow of -$130 million less capital expenditures of $31,000 gives free cash flow of -$130 million for fiscal 2025.